EAvid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	799M 701M 646M 602M 1.13B 75.95B 1.16B 7.77B 3.01B 37.28B 3B 2.93B 130B	P/E 2023	2,007x	P/E 2024	-3.42x
Enterprise Value	964M 847M 779M 726M 1.37B 91.67B 1.4B 9.37B 3.63B 45B 3.62B 3.54B 157B	EV / Sales 2023	8.58x	EV / Sales 2024	4.64x
Free-Float	98.58%	Yield 2023 *	-	Yield 2024	-

05-18	Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer	CI
05-11	Avid Bioservices, Inc. Appoints Kerri McCullough Wood as Chief Commercial Officer	CI
02-24	Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California	CI
01-15	Avid Bioservices Appoints Rich Mcavoy as Chief Business Officer	CI
11-10	Avid Bioservices Appoints Dave Stewart as Chief Technology and Transformation Officer	CI
25-09-15	Avid Bioservices Announces CEO Changes	CI
25-02-06	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Biotechnology Select Industry Index	CI
25-02-06	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Global BMI Index	CI
25-02-06	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P TMI Index	CI
25-02-05	Avid Bioservices, Inc. Announces Cessation of Board and Committee Members	CI
25-02-04	Funds managed by GHO Capital Partners LLP and Ampersand Management LLC completed the acquisition of Avid Bioservices, Inc. from a group of shareholders.	CI
25-02-04	Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from NASDAQ Composite Index	CI
25-01-30	Avid Shareholders Approve Acquisition by GHO, Ampersand	MT

24-12-04	Stephens Downgrades Avid Bioservices to Equalweight, Price Target is $12.50	MT
24-11-07	RBC Capital Downgrades Avid Bioservices to Sector Perform From Outperform, Adjusts PT to $12.50 From $12	MT
24-11-07	RBC Capital Downgrades Avid Bioservices to Sector Perform, Price Target is $12.50	MT
24-09-10	Avid Bioservices Shares Jump as RBC Boosts Price Target After Bookings Beat	MT
24-09-10	RBC Raises Price Target on Avid Bioservices to $12 From $8, Maintains Outperform Rating	MT

25-02-10	Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience	AQ
25-02-06	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ
25-02-05	Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger	GL
25-02-05	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	GL
25-02-05	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners	AQ

Manager	Title	Age	Since
Kenneth Bilenberg CEO	Chief Executive Officer	-	2025-09-14
Richard McAvoy DFI	Director of Finance/CFO	-	2026-05-31
David Stewart CTO	Chief Tech/Sci/R&D Officer	-	2025-10-31

Peregrine Pharmaceuticals Stock Nasdaq

Stocks

US7136615025

Pharmaceuticals

Valuation: Peregrine Pharmaceuticals

Latest news : Peregrine Pharmaceuticals

Analysts' recommendations: Peregrine Pharmaceuticals

Press Releases: Peregrine Pharmaceuticals

News in other languages: Peregrine Pharmaceuticals

Quotes and Performance

Managers and Directors: Peregrine Pharmaceuticals

Biopharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEREGRINE PHARMACEUTICALS	+2.44%	+8.76%	-	-	799M
REGENERON PHARMACEUTICALS, INC.	+0.19%	+0.21%	+16.79%	-13.06%	63.56B
UCB	+1.05%	+1.56%	+56.33%	+227.72%	55.92B
SAMSUNG BIOLOGICS CO.,LTD.	+0.36%	+39.60%	+39.60%	+39.60%	41.68B
CSL LIMITED	-0.52%	+0.08%	-50.89%	-57.38%	39.12B
BIOGEN INC.	-2.93%	+5.09%	+61.25%	-26.37%	30.97B
MODERNA, INC.	+3.53%	+19.99%	+152.70%	-40.33%	28.77B
INCYTE CORPORATION	+0.40%	+4.93%	+65.59%	+82.83%	22.74B
INNOVENT BIOLOGICS, INC.	+7.22%	+12.16%	+7.63%	+184.50%	17.64B
SWEDISH ORPHAN BIOVITRUM AB	+0.19%	-0.13%	+64.47%	+125.46%	16.66B
Average	+1.19%	+4.68%	+45.94%	+58.11%	35.23B
Weighted average by Cap.	+0.69%	+3.82%	+40.58%	+52.23%

	2023	2024
Net sales	149M 131M 121M 112M 212M 14.19B 216M 1.45B 562M 6.97B 560M 548M 24.24B	140M 123M 113M 105M 199M 13.3B 203M 1.36B 527M 6.53B 525M 514M 22.72B
Net income	560K 492K 453K 422K 795K 53.24M 811K 5.44M 2.11M 26.13M 2.1M 2.06M 90.95M	-141M -124M -114M -106M -200M -13.38B -204M -1.37B -530M -6.57B -528M -517M -22.86B
Net Debt	151M 133M 122M 114M 215M 14.38B 219M 1.47B 570M 7.06B 568M 556M 24.56B	165M 145M 134M 125M 235M 15.72B 240M 1.61B 623M 7.72B 621M 607M 26.85B